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A B S T R A C T
We have generated two human induced pluripotent stem cell (iPSC) lines from CD133+ cells isolated from umbilical cord blood (CB) of a female child using non-
integrative Sendai virus. Here we describe the complete characterization of these iPSC lines: PRYDi-CB5 and PRYDi-CB40.
Resource table.








Institution Inbiomed Foundation (San Sebastian, Spain)
Contact information of
distributor
A. Giorgetti, agiorgetti@cmrb.eu; X. Carvajal-Vergara,
xcarvajal@unav.es
Type of cell lines iPSCs
Origin Human





Multiline rationale isogenic clones
Gene modification NO
Type of modification N/A
Associated disease N/A
Gene/locus N/A
Method of modification N/A

















Ethical approval Patient informed consent obtained by the Ethical
Committee of Clinical Investigation of Donostia Hospital
(Approval no. 9/05)
Resource utility
These human iPSC lines were derived from umbilical cord CD133+
cells using Sendai virus that is a negative sense, single strand RNA virus
that allows the generation of iPSCs without the transgene integration.
These cells could be used as integration-free control iPSC lines.
Resource details
CD133 antigen is known as a stem cell marker for hematopoietic
stem cells (HSCs) and progenitors, and is a valid substitute for CD34,
commonly used for HSCs enrichment. Moreover, since CD133 is not
expressed in late hematopoietic progenitors, this allows for the selec-
tion of a more homogeneous population enriched in HSC. Of note, CB
CD133+ cells express a subset of pluripotency-associated genes (OCT4,
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Fig. 1. Characterization of PRYDi-CB5 (CBiPS5) and PRYDi-CB40 (CBiPS40) human iPSC lines. A) A representative iPSC colony in bright field is shown. B)
Analysis of the AP activity. C) Endogenous expression of pluripotency-associated genes (OCT4, SOX2, NANOG and ZFP42) by RT-qPCR. D) OCT4 and SSEA3
immunostaining. Nuclei: DAPI. E) Gene expression analysis by RT-qPCR of NEUROD3 (ectoderm), MEOX (mesoderm), and FOXA2 (endoderm) in undifferentiated
(day 0) and differentiated iPSC (day 14). F) TUJ1 (ectoderm), SMA (mesoderm) and AFP (endoderm) protein expression analysis by immunostaining in un-
differentiated (day 0) and differentiated iPSC (day 14). Nuclei: DAPI. G) Immunofluorescence analysis of TUJ1/GFAP (ectoderm), ACTIN/SMA (mesoderm) and AFP
(endoderm) proteins in teratomas derived from the two iPSC lines. Nuclei: DAPI.
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SOX2, NANOG and CRIPTO), albeit at much lower levels than human
embryonic stem cells (HESCs) (Giorgetti et al., 2009). On the other
hand, the endogenous levels of cMYC and KLF4 are higher in CB
CD133+ cells compared with other adult somatic cells. The combina-
tion of low levels of pluripotency markers with the high levels of KLF4
and c-MYC allow enhanced reprogramming of CB CD133+cells.
CD133+ cells were isolated and infected with non-integrative
Sendai virus vectors encoding OCT4, SOX2, KLF4, c-MYC. On day 3
after infection, cells were transferred onto plates containing a layer of
irradiated mouse fibroblast feeders (MEFs) and cultured until human
pluripotent stem cells-like colonies were observed, approximately
3 weeks post-infection. Colonies were manually picked for clonal ex-
pansion. Multiple iPSC clones were generated and here we show the
characterization of two of these established iPSC lines, PRYDi-CB5 and
PRYDi-CB40. The short tandem repeats (STR) analysis confirmed the
genetic relatedness of both iPSC lines to their parental CB sample. These
iPSC lines formed large and flat polygonal colonies of different shapes
with smooth edges (Fig. 1A) and showed a high alkaline phosphatase
(AP) activity (Fig. 1B).
Endogenous pluripotency-related transcription factors such OCT4,
NANOG, SOX2 and ZFP42 were expressed (Fig. 1C). OCT4 transcription
factor was expressed in the nucleus and SSEA3 pluripotency-related
antigen was present in the surface of the iPSCs, assessed by immuno-
fluorescence (Fig. 1D). Established cell lines were karyotypically
normal (Sup Fig. 1A) and mycoplasma free (Sup. Fig. 1B). These iPSC
lines have the potential to differentiate into cells of the three germ
layers both in vitro and in vivo. Upon the in vitro differentiation of these
iPSC lines, using an embryoid body (EB) differentiation assay (Carvajal-
Vergara et al., 2010), ectoderm (NEUROD1 or TUJ1), mesoderm
(MEOX or SMA) and endoderm (FOXA2 or AFP) markers were ex-
pressed, analyzed by RT-qPCR (Fig. 1E) or immunofluorescence
staining (Fig. 1F), respectively. These cell lines were able to develop
teratomas two months after their injection in NOD-SCID im-
munodeficient mice, and the immunohistological staining analysis
confirmed that cells derived from the three germ layers such as TUJ1+/
GFAP+ (ectoderm), ACTIN+/SMA+ (mesoderm) and AFP+ (en-
doderm) were present (Fig. 1G).
Materials and methods
Generation of non-transgenic iPSCs
CB CD133+ hematopoietic stem cells were isolated and cultivated
as described in Giorgetti et al., 2009. One hundred thousand cells were
transduced with CytoTune™-iPS 2.0 Sendai Reprogramming Kit (In-
vitrogen) at 37 °C for 24 h in CD133+ growth medium containing 8 μg/
mL polybrene. iPSCs were cultured on irradiated MEFs with KO-DMEM
20% KSR medium supplemented with Glutamax, penicillin/strepto-
mycin, non-essential aminoacids (all from Gibco), b-mercaptoethanol
(Sigma-Aldrich) and 20 ng/mL of bFGF (Peprotech) in an incubator
with 5% CO2 in air. The iPSC were passaged (1:6 ratio) every 5–6 days
using 200 U/mL Collagenase IV (Gibco). After their characterization,
these iPSC lines have also been adapted into feeder-free culture con-
ditions at CIMA institute (Pamplona, Spain) and the iPSC lines can be
grown on Corning Matrigel hESC-Qualified Matrix in mTeSR™1
medium (STEMCELL Technologies). We regularly harvest iPSCs every
4 days with TrypLE Express (Gibco) and seed approximately 300,000
cells per well of a 6-multiwell plate in mTeSR™1 supplemented with Y-
27632 (STEMCELL Technologies) at 10 μM (Tables 1 and 2).
Cells were regularly tested for mycoplasma contamination by
MycoAlert Mycoplasma Test (Lonza) and contaminations have not been
detected.
STR analysis
To verify that human PRYDi-CB5 (CBiPS5) and PRYDi-CB40
(CBiPS40) iPSC lines derived from their parental CB sample, we per-
formed STR analysis of three loci (D10S1214, D17S1290 and D7S796).
The genomic DNA (gDNA) was isolated with Easy-DNA™ kit
(Invitrogen). The PCR amplification was performed using a total of
50ng of gDNA per reaction, the Taq polymerase with Standard Taq
Buffer (New England Biolabs) and the primers listed in Table 3. The
PCR conditions were as follows: 5 min at 94 °C, 35 x (5min at 94 °C,
1min at 55 °C and 1min at 72 °C) and 7min at 72 °C. A 2.5% agarose
gel was used to analyze PCR products. A positive control, gDNA from
the parental CB sample and a negative control, gDNA from BJ fibro-
blasts, was used.
Karyotyping
The iPSCs were grown on a T75 flask without feeders. Chromosomal
analysis was performed in PRYDi-CB5 and PRYDi-CB40 at passage 8
and 10, respectively, using the standard GTG-banding method at the
Genetics Service (Policlínica Gipuzkoa, San Sebastián). 15 metaphases
per cell line were analyzed.
Immunofluorescence (IF) staining and alkaline phosphatase (AP)
The iPSCs or iPSC-derived differentiated cells were fixed with 4%
paraformaldehyde for 15min at room temperature. Pluripotency-asso-
ciated (OCT4, NANOG, SOX2, SSEA3 and TRA-1-60) and differentiation
(TUJ1, SMA, AFP) markers staining was performed as previously de-
tailed (Carvajal-Vergara et al., 2010). Cells were counterstained with
DAPI (Sigma) and analyzed with Zeiss LSM510-META confocal laser
scanning microscope. AP Blue Membrane Substrate Solution was used
following the manufacturer's instructions (Sigma-Aldrich).
Teramotas were fixed in 4% paraformaldehyde and embedded in
paraffin. Slices of 5 um were obtained with a microtome. Antigen re-
trieval was performed with citrate buffer and nonspecific labelling was
blocked in TBS 0.5% Triton blocking solution containing 3% donkey
serum. Primary antibodies were diluted in blocking solution and in-
cubated for 24 h at 4 °C. After washing in TBS the sections were in-
cubated with their corresponding secondary antibody for 2 h at 37 °C.
Finally, sections were washed, counterstained with DAPI and cover-
slipped with mounting medium.
All the primary and secondary antibodies used in this study are
referenced in Table 3.
RT-qPCR
Total RNA was prepared with the RNeasy Mini Kit (QIAGEN) and
reverse transcribed with Superscript III (ThermoFisher). Quantitative
PCR (qPCR) analysis was performed in the StepOnePlus™ Real-Time
PCR System using the power SyBR PCR green Master Mix. Sequences of
pluripotency- and specific lineage-related markers primers are de-
scribed in Table 3. The quantitative gene expression data were
Table 1
Summary of lines.
iPSC line names Abbreviation in figures Gender Age Ethnicity Genotype of locus Disease
PRYDi-CB5 CBiPS5 Female Newborn N/A N/A N/A
PRYDi-CB40 CBiPS40 Female Newborn N/A N/A N/A
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normalized to expression levels of GAPDH housekeeping genes and
error bars indicate± s.d. of triplicates.
In vitro and in vivo differentiation
We used the in vitro differentiation procedure described in Carvajal-
Vergara et al., 2010. Briefly, iPSC colonies detached with collagenase IV
were disaggregated and dispersed into small clumps and cultured as EBs
in iPSC medium without bFGF in ultra-low attachment plates (Corning
Inc.). On day 1 the media was changed and EBs were cultured in
StemPro34 medium supplemented with Glutamax, Pen/Strep (all from
Gibco), 50 μg/mL ascorbic acid, 150 μg/mL transferrin and 4×10−4 1-
Thioglycerol (Sigma-Aldrich). On day 8 of differentiation, EBs were
plated on 0.1% gelatin coated dishes and cultured in DMEM 10% FBS
supplemented with Glutamax and Pen/Strep (all from Gibco) differ-
entiation medium for 8 additional days before RNA collection for RT-
Table 2
Characterization and validation.
Classification Test Result Data
Morphology Bright field normal Fig. 1A
Phenotype AP Activity shown Fig. 1B
RT-qPCR Expression of endogenous pluripotency markers OCT4, SOX2,
NANOG, ZFP42
Fig. 1C
Immunofluorescence (IF) staining. Positive staining for SSEA3 and OCT4 Fig. 1D
Genotype Karyotype 46 XX
Resolution: 400 bps
Sup. Fig.1A
Identity STR analysis 3 loci tested, all matched Available with the Authors
Mutation analysis (IF APPLICABLE) Southern Blot OR WGS N/A N/A
Microbiology and virology Mycoplasma Mycoplasma testing by luminescence Negative Sup. Fig.1B
Differentiation potential Embryoid body formation Expression of germ layer markers:
Ectoderm: NEUROD3 (RT-qPCR); TUJ1 (IF)
Mesoderm: MEOX (RT-qPCR); SMA (IF)
Endoderm: FOXA2 (RT-qPCR); AFP (IF)
Fig. 1E
Fig. 1F





Donor screening (OPTIONAL) HIV 1+2 Hepatitis B, Hepatitis C N/A N/A
Genotype additional info (OPTIONAL) Blood group genotyping N/A N/A
HLA tissue typing N/A N/A
Table 3
Reagents details.
Antibodies used for immunocytochemistry/flow-cytometry
Antibody Dilution Company Cat # and RRID
Pluripotency markers Rabbit anti-OCT4 1:200 BioVision Cat#3576-100 RRID#AB_2167563
Rabbit anti-SOX2 1:75 Thermo Fisher Scientific Cat#PA1-16968 RRID#AB_2195781
Goat anti-NANOG 1:50 Everest Biotech Cat#EB06860 RRID#AB_2150379
Rat anti-SSEA3 1:4 Hyrbridoma Bank Cat#MC-631 RRID#AB_528476
Mouse IgM anti-TRA-1-60 1:200 Thermo Fisher Scientific Cat#14-8863-80 RRID#AB_891612
Lineage-specific markers of the three germ layers Rabbit anti-AFP 1:400 Agilent Cat#A0008 RRID#AB_2650473
Rabbit anti-GFAP 1:500 Agilent Cat#Z0334 RRID#AB_10013382
Mouse anti-TUJ1 1:500 Covance Research Products Inc. Cat#MMS-435P RRID#AB_2313773
Mouse IgG2a anti-SMA 1:400 Sigma-Aldrich Cat#A5228 RRID#AB_262054
Mouse IgM anti-ACTIN 1:400 Sigma-Aldrich Cat#A2172 RRID#AB_476695
Secondary antibodies Alexa Fluor 546 Goat anti-Rabbit 1:1000 Thermo Fisher Scientific Cat#A-11035 RRID#AB_2534093
Alexa Fluor 488 Donkey anti-Goat 1:500 Thermo Fisher Scientific Cat#A-11055 RRID#AB_142672
Alexa Fluor 488 Goat anti-Rat 1:500 Thermo Fisher Scientific Cat#A-11006 RRID#AB_2534074
Alexa Fluor 488 Goat anti-Mouse IgM 1:500 Thermo Fisher Scientific Cat#A-21042 RRID#AB_2535711
Alexa Fluor 488 Donkey anti-Rabbit 1:500 Thermo Fisher Scientific Cat#A-21206 RRID#AB_2535792
Cy™3 Donkey anti-Mouse 1:500 Thermo Fisher Scientific Cat#A-11035 RRID#AB_2534093
Primers
Target (product size) Forward/Reverse primer (5′-3′)
Pluripotency markers (qPCR) OCT4 (123 bp) AACCTGGAGTTTGTGCCAGGGTTT/TGAACTTCACCTTCCCTCCAACCA
SOX2 (150 bp) AGAAGAGGAGAGAGAAAGAAAGGGAGAGA/GAGAGAGGCAAACTGGAATCAGGATCAAA
NANOG (190 bp) CCTGAAGACGTGTGAAGATGAG/GCTGATTAGGCTCCAACCATAC
ZFP42 (267 bp) AAAGCATCTCCTCATTCATGGT/TGGGCTTTCAGGTTATTTGACT
Differentiation markers (qPCR) NEUROD1 (200 bp) CCCATGGTGGGTTGTCATATATTCATGT/CCAGCATCACATCTCAAACAGCAC
MEOX (171 bp) TGGAAGCGTGTGAAGGGAGGT/AAGGAAGAGGGTGAAGGTGGGATTG
FOXA2 (107 bp) GCATTCCCAATCTTGACACGGTGA/GCCCTTGCAGCCAGAATACACATT
House-Keeping Genes (qPCR) GAPDH (87 bp) TGCACCACCAACTGCTTAGC/GGCATGGACTGTGGTCATGAG
Identity (PCR) D10S1214 ATTGCCCCAAAACTTTTTTG/TTGAAGACCAGTCTGGGAAG
D17S1290 GCCAACAGAGCAAGACTGTC/GGAAACAGTTAAATGGCCAA
D7S796 TTTTGGTATTGGCCATCCTA/GAAAGGAACAGAGAGACAGGG
E. Arellano-Viera, et al. Stem Cell Research 36 (2019) 101410
4
qPCR or cell fixation for immunostaining analyses.
To test the in vivo differentiation capability of iPSCs, one million
cells were harvested with TrypLE, suspended in 100 ul of 50% (v/v)
Matrigel (Corning) and 50% (v/v) PBS and injected intratesticularly in
an 8-week old NOD-SCID mouse. Teratoma formation was observed
after 2months of infusion. The teratoma was sectioned and stained.
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